292 related articles for article (PubMed ID: 32685545)
1. Shenmai Injection Supresses Glycolysis and Enhances Cisplatin Cytotoxicity in Cisplatin-Resistant A549/DDP Cells via the AKT-mTOR-c-Myc Signaling Pathway.
Sun Y; Chen Y; Xu M; Liu C; Shang H; Wang C
Biomed Res Int; 2020; 2020():9243681. PubMed ID: 32685545
[TBL] [Abstract][Full Text] [Related]
2. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.
Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M
Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719
[TBL] [Abstract][Full Text] [Related]
3. TRIM59 knockdown blocks cisplatin resistance in A549/DDP cells through regulating PTEN/AKT/HK2.
He R; Liu H
Gene; 2020 Jul; 747():144553. PubMed ID: 32165307
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
Gong T; Cui L; Wang H; Wang H; Han N
J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
[TBL] [Abstract][Full Text] [Related]
5. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
Xia A; Li H; Li R; Lu L; Wu X
Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
[TBL] [Abstract][Full Text] [Related]
6. Glycometabolic adaptation mediates the insensitivity of drug-resistant K562/ADM leukaemia cells to adriamycin via the AKT-mTOR/c-Myc signalling pathway.
Zhang X; Ai Z; Chen J; Yi J; Liu Z; Zhao H; Wei H
Mol Med Rep; 2017 Apr; 15(4):1869-1876. PubMed ID: 28259993
[TBL] [Abstract][Full Text] [Related]
7. PRDM14 mediates chemosensitivity and glycolysis in drug‑resistant A549/cisplatin cells and their progenitor A549 human lung adenocarcinoma cells.
He S; Ma X; Zheng N; Wang G; Wang M; Xia W; Yu D
Mol Med Rep; 2021 Feb; 23(2):. PubMed ID: 33355367
[TBL] [Abstract][Full Text] [Related]
8. Salvianolic acid A reverses cisplatin resistance in lung cancer A549 cells by targeting c-met and attenuating Akt/mTOR pathway.
Tang XL; Yan L; Zhu L; Jiao DM; Chen J; Chen QY
J Pharmacol Sci; 2017 Sep; 135(1):1-7. PubMed ID: 28939129
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of polyphyllins I and VII on human cisplatin-resistant NSCLC via p53 upregulation and CIP2A/AKT/mTOR signaling axis inhibition.
Feng FF; Cheng P; Sun C; Wang H; Wang W
Chin J Nat Med; 2019 Oct; 17(10):768-777. PubMed ID: 31703757
[TBL] [Abstract][Full Text] [Related]
10. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling.
Wang HJ; Yang ZX; Dai XT; Chen YF; Yang HP; Zhou XD
Apoptosis; 2017 Sep; 22(9):1157-1168. PubMed ID: 28677094
[TBL] [Abstract][Full Text] [Related]
11. Depleted aldehyde dehydrogenase 1A1 (ALDH1A1) reverses cisplatin resistance of human lung adenocarcinoma cell A549/DDP.
Wei Y; Wu S; Xu W; Liang Y; Li Y; Zhao W; Wu J
Thorac Cancer; 2017 Jan; 8(1):26-32. PubMed ID: 27813328
[TBL] [Abstract][Full Text] [Related]
12. Niclosamide enhances the cytotoxic effect of cisplatin in cisplatin-resistant human lung cancer cells via suppression of lung resistance-related protein and c-myc.
Zuo Y; Yang D; Yu Y; Xiang M; Li H; Yang J; Li J; Jiang D; Zhou H; Xu Z; Yu Z
Mol Med Rep; 2018 Mar; 17(3):3497-3502. PubMed ID: 29257330
[TBL] [Abstract][Full Text] [Related]
13. Effects of VBMDMP on the reversal of cisplatin resistance in human lung cancer A549/DDP cells.
Wang CK; Zhang Y; Zhang ZJ; Qiu QW; Cao JG; He ZM
Oncol Rep; 2015 Jan; 33(1):372-82. PubMed ID: 25394854
[TBL] [Abstract][Full Text] [Related]
14. TAZ inhibition restores sensitivity of cisplatin via AKT/mTOR signaling in lung adenocarcinoma.
Xu W; Wei Y; Li Y; Yin Y; Yuan W; Yang Y; Zhao W; Wu J
Oncol Rep; 2017 Sep; 38(3):1815-1821. PubMed ID: 28737828
[TBL] [Abstract][Full Text] [Related]
15. CNTN-1 Enhances Chemoresistance in Human Lung Adenocarcinoma Through Induction of Epithelial-Mesenchymal Transition by Targeting the PI3K/Akt Pathway.
Zhang R; Sun S; Ji F; Liu C; Lin H; Xie L; Yang H; Tang W; Zhou Y; Xu J; Li P
Cell Physiol Biochem; 2017; 43(2):465-480. PubMed ID: 28934754
[TBL] [Abstract][Full Text] [Related]
16. Jolkinolide B inhibits glycolysis by downregulating hexokinase 2 expression through inactivating the Akt/mTOR pathway in non-small cell lung cancer cells.
Gao X; Han H
J Cell Biochem; 2018 Jun; 119(6):4967-4974. PubMed ID: 29384225
[TBL] [Abstract][Full Text] [Related]
17. Reversal of cisplatin resistance by inhibiting PI3K/Akt signal pathway in human lung cancer cells.
Zhang Y; Bao C; Mu Q; Chen J; Wang J; Mi Y; Sayari AJ; Chen Y; Guo M
Neoplasma; 2016; 63(3):362-70. PubMed ID: 26925782
[TBL] [Abstract][Full Text] [Related]
18. Autophagy facilitates lung adenocarcinoma resistance to cisplatin treatment by activation of AMPK/mTOR signaling pathway.
Wu T; Wang MC; Jing L; Liu ZY; Guo H; Liu Y; Bai YY; Cheng YZ; Nan KJ; Liang X
Drug Des Devel Ther; 2015; 9():6421-31. PubMed ID: 26715839
[TBL] [Abstract][Full Text] [Related]
19. miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET.
Chen QY; Jiao DM; Wang J; Hu H; Tang X; Chen J; Mou H; Lu W
Oncotarget; 2016 Apr; 7(17):24510-26. PubMed ID: 27014910
[TBL] [Abstract][Full Text] [Related]
20. Silencing long non-coding RNA ROR improves sensitivity of non-small-cell lung cancer to cisplatin resistance by inhibiting PI3K/Akt/mTOR signaling pathway.
Shi H; Pu J; Zhou XL; Ning YY; Bai C
Tumour Biol; 2017 May; 39(5):1010428317697568. PubMed ID: 28459375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]